Heat Biologics, Inc. (NASDAQ:HTBX) was the recipient of a significant decrease in short interest in September. As of September 29th, there was short interest totalling 1,429,337 shares, a decrease of 33.8% from the September 15th total of 2,159,713 shares. Based on an average trading volume of 312,051 shares, the days-to-cover ratio is presently 4.6 days. Currently, 4.2% of the shares of the stock are short sold.

Heat Biologics (NASDAQ:HTBX) opened at 0.63 on Wednesday. Heat Biologics has a 52-week low of $0.46 and a 52-week high of $3.35. The stock’s market cap is $22.55 million. The firm has a 50-day moving average price of $0.62 and a 200 day moving average price of $0.64.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. increased its position in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 661,388 shares of the biopharmaceutical company’s stock after buying an additional 70,290 shares during the quarter. Vanguard Group Inc. owned about 1.86% of Heat Biologics worth $403,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.74% of the company’s stock.

Several research analysts have issued reports on the company. Zacks Investment Research cut Heat Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Noble Financial reiterated a “buy” rating on shares of Heat Biologics in a research report on Tuesday, July 4th. ValuEngine cut Heat Biologics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Griffin Securities assumed coverage on Heat Biologics in a research report on Tuesday, September 12th. They issued a “buy” rating and a $2.25 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $2.13.

ILLEGAL ACTIVITY WARNING: “Heat Biologics, Inc. (HTBX) Sees Significant Drop in Short Interest” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/heat-biologics-inc-htbx-sees-significant-drop-in-short-interest/1637590.html.

About Heat Biologics

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.